Corcept Therapeutics is trading at $32.15, down 72.64% after hours after a $117.50 close on September 22, 2026; no credible company-specific explanation was found.
- The regular session gained 3.29%, supported by broader biotechnology strength.
- The latest identifiable company news was the positive September 18 CHMP recommendation supporting European approval of relacorilant; a final European Commission decision is expected in the fourth quarter.
- The decline remains unexplained; rechecking for a delayed filing or pricing-data issue may be warranted.